In the present study, MCPyV DNA was detected in 22.7% (34 of 150) of NSCLC tissues and 8.0% (12 of 150) of adjacent non-NSCLC tissues from Korean patients (Table 1 and Figure 1). Among the 150 patients enrolled, 80 had AD, 63 had SCC, and 7 had other NSCLCs (including pleomorphic carcinomas). Among the 80 ADs, 22 (27.5%) tested positive for MCPyV sequences; among the 63 SCCs, 10 (15.9%) tested positive. Notably, among the 34 positive-NSCLC samples, MCPyV DNA was detected in 64.7% (22 of 34) of the ADs and 29.4% (10 of 34) of the SCCs. Among the 12 positive-adjacent nonlung cancer samples, MCPyV DNA was detected in 91.7% (11 of 12) of the AD samples and 8.3% (1 of 12) of the SCC samples.